ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given a consensus rating of “Buy” by the nine research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $80.13.

A number of analysts have issued reports on ANIP shares. StockNews.com lowered shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 24th. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research report on Monday, April 21st. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 price objective on the stock. Guggenheim reiterated a “buy” rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Friday, April 11th. Finally, JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,200 shares of company stock worth $197,792. 12.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE grew its position in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 531 shares during the last quarter. KBC Group NV grew its position in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the last quarter. GAMMA Investing LLC increased its stake in ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after purchasing an additional 881 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $166,000. Finally, Rafferty Asset Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $200,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Up 0.1 %

Shares of NASDAQ ANIP opened at $70.82 on Thursday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $1.54 billion, a PE ratio of -128.76 and a beta of 0.49. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $72.57. The stock has a fifty day simple moving average of $64.94 and a 200-day simple moving average of $60.14.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.